Novavax Inc (NVAX)
8.47
+0.43
(+5.35%)
USD |
NASDAQ |
Nov 22, 16:00
8.44
-0.03
(-0.35%)
After-Hours: 20:00
Novavax Revenue (TTM): 847.25M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 847.25M |
| June 30, 2024 | 784.80M |
| March 31, 2024 | 793.74M |
| December 31, 2023 | 693.46M |
| September 30, 2023 | 727.89M |
| June 30, 2023 | 1.334B |
| March 31, 2023 | 1.096B |
| December 31, 2022 | 1.707B |
| September 30, 2022 | 692.39M |
| June 30, 2022 | 242.93M |
| March 31, 2022 | 355.02M |
| December 31, 2021 | 197.58M |
| September 30, 2021 | 750.54M |
| June 30, 2021 | 728.72M |
| March 31, 2021 | 466.24M |
| December 31, 2020 | 22.39M |
| September 30, 2020 | 204.76M |
| June 30, 2020 | 50.24M |
| March 31, 2020 | 18.06M |
| December 31, 2019 | 18.66M |
| September 30, 2019 | 15.97M |
| June 30, 2019 | 21.20M |
| March 31, 2019 | 28.62M |
| December 31, 2018 | 34.29M |
| September 30, 2018 | 38.57M |
| Date | Value |
|---|---|
| June 30, 2018 | 39.19M |
| March 31, 2018 | 35.15M |
| December 31, 2017 | 31.18M |
| September 30, 2017 | 26.16M |
| June 30, 2017 | 21.04M |
| March 31, 2017 | 16.82M |
| December 31, 2016 | 15.35M |
| September 30, 2016 | 15.81M |
| June 30, 2016 | 19.10M |
| March 31, 2016 | 30.59M |
| December 31, 2015 | 36.25M |
| September 30, 2015 | 37.12M |
| June 30, 2015 | 38.81M |
| March 31, 2015 | 33.07M |
| December 31, 2014 | 30.66M |
| September 30, 2014 | 32.68M |
| June 30, 2014 | 29.27M |
| March 31, 2014 | 24.54M |
| December 31, 2013 | 20.91M |
| September 30, 2013 | 16.73M |
| June 30, 2013 | 17.70M |
| March 31, 2013 | 21.27M |
| December 31, 2012 | 22.08M |
| September 30, 2012 | 23.36M |
| June 30, 2012 | 22.60M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
18.06M
Minimum
Mar 2020
1.707B
Maximum
Dec 2022
586.56M
Average
692.93M
Median
Revenue (TTM) Benchmarks
| Pfizer Inc | 59.37B |
| Moderna Inc | 5.056B |
| Inovio Pharmaceuticals Inc | -- |
| Baxter International Inc | 17.28B |
| Halozyme Therapeutics Inc | 947.36M |